CReDO 2020 workshop
The Tata Memorial Centre, Mumbai and the National Cancer Grid of India conducted the fifth CReDO workshop at Lonavla, near Mumbai
between 1 st and 7 th March 2020.
Tata Trusts, Mumbai
Tata Memorial Centre, Mumbai
King’s College, London
American Society of Clinical Oncology
Cancer Research UK
Indian Council of Medical Research
US National Cancer Institute through the CRDF grant
The Medical Oncology Group of Australia (MOGA) Incorporated through the Australia and Asia Pacific
Clinical Oncology Research Development (ACORD) Initiative
Medical Research Council - Clinical Trials Unit at University College London
This conference was organized under the auspices of the European Organisation for Research and Treatment of Cancer (EORTC)
Pre-workshop online learning was facilitated by Project ECHO.
|Clinical Oncologist and Senior Visiting Research Fellow at The Institute of Cancer Policy, King’s College, London
|Medical Oncologist and Health Services Researcher at Queen’s University, Kingston, Canada
|Founder, International Drug Development Institute and CluePoints, Belgium and USA
|Reader in Global Health and Social Medicine at King’s College London, Director of Postgraduate Research Studies and Chair of the Culture, Medicine and Power research group
|Professor in Paediatric Oncology, Tata Memorial Centre, Mumbai
|Editor-in-Chief, Lancet Oncology
|Professor of Biostatistics, University of Otago, New Zealand
|Consultant, Tata Memorial Research Administrative Council
|Professor of Epidemiology & Medical Statistics at University College London, and Deputy Director of the Cancer Research UK & UCL Cancer Trials Centre
|Mathematical Statistician, Biostatistics Research Group, National Institute of Allergy and Infectious Disease, USA
|Consultant Hematologist, Peter MacCallum Cancer Centre, Melbourne
|Professor of Research, University of Southern California and a Senior Statistician with the Childrens’ Oncology Group.
|Medical Oncologist, Medical Research Council – Clinical Trials Unit at University College London
|Marie-Cecile Le Deley
|Associate Professor of Biostatistics at University Paris-Sud / Paris-Saclay and Head of the Biostatistics and Methodology Unit of Oscar Lambret Cancer Centre
|Senior Consultant, Department of Radiation Oncology, Tata Medical Center, Kolkata
|Professor & Head, Department of Biostatistics, JIPMER
|Professor of Biostatistics at the University of Versailles St Quentin and at the Institut Curie, Paris
|Professor of Medical Statistics and Epidemiology and Director of the MRC Clinical Trials Unit at UCL and the Institute of Clinical Trials and Methodology at University College London.
|Professor, Department of Digestive Diseases and Clinical Nutrition, Tata Memorial Centre, Mumbai
|C S Pramesh
|Professor, Thoracic Surgery, Tata Memorial Centre and Co-ordinator, National Cancer Grid of India
|Professor of Breast Cancer at King’s College London and Director of King’s Health Partners Comprehensive Cancer Centre
|Professor of Anaesthesiology, Tata Memorial Centre, Mumbai
|Chief Editor, Nature Reviews Clinical Oncology
|US Health Attache for India and Regional Representative for South Asia, Department of Health and Human Services
|Professor, Adult hematolymphoid disease management group, Medical Oncology and Officer-in-charge, Clinical Research Secretariat, Tata Memorial Centre
|Professor of Experimental Cancer Medicine, King’s College London, and Consultant in Medical Oncology, Guy’s and St. Thomas’ Hospitals London, UK
|Professor of Oncology and Clinical Epidemiology, University of Sydney and Oncology Co-Director at the NHMRC Clinical Trials Centre
|Professor of Cancer and Global Health at Kings College London and Director of the Institute of Cancer Policy
|Emeritus Professor of Medicine and Medical Biophysics at Princess Margaret Cancer Centre and University of Toronto
|Assistant Professor, Head and Neck surgical oncology, Tata Memorial Centre
|Professor of Medicine and Director of the Division of Palliative Medicine at the University of Toronto
Adam Fundytus Alberta Health Services, Canada
Adhara Chakraborty Tata Memorial Centre, Mumbai
Akhil Rajendra Tata Memorial Centre, Mumbai
Amrut Kadam S Bangalore Medical College & Research Institute, Bangalore
Anand Narayan Chinnachamy GKNM Hospital, Coimbatore
Anjum Joad Bhagwan Mahaveer Cancer Hospital, Jaipur
Anupama Borker Goa Medical College
Archi Agrawal Tata Memorial Centre, Mumbai
Arjun Mandade M.S. Ramaiah Medical college, Bangalore
Arpitha Anantharajju JIPMER, Puduchery
Ashok Kumar Das Dr B. Borooah Cancer Institute, Guwahati
Baphiralyne Wankhar NEIGRIHMS, Shillong
Bhavika Kothari Tata Memorial Centre, Mumbai
Bishesh Sharma Poudyal Civil Service Hospital, Nepal
Chetan Anil Dhamne Tata Memorial Centre, Mumbai
Deepa Joseph AIIMS, Rishikesh
Divya Pillai Clinical Development Services Agency, New Delhi
Dorothy Lombe Government Republic of Zambia
Fidel Rubagumya Ministry of Health, Rwanda
Florida Sharin Tata Memorial Centre, Mumbai
Fouzia Aboobacker Christian Medical College, Vellore, Tamil Nadu
Gangothri Selvarajan Cancer Institute, Adayar, Chennai
Hemantkumar Onkar Nemade Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad
Jyothsna Kuriakose Tata Memorial Centre, Mumbai
Kanika Batra Modi Max Hospital, Saket, New Delhi
Karthik Rengaraj Tata Memorial Centre, Mumbai
Krishnakumar Thankappan Amrita Institute of Medical Sciences, Kochi
Mahendra Pal Tata Memorial Centre, Mumbai
Mayur Raman Mantri Tata Memorial Centre, Mumbai
Mingma Sherpa Sikkim Manipal Institute of Medical Sciences, Gangtok, Sikkim
Nagarajan Murugaiyan GKNM Hospital, Coimbatore
Nandini Menon Tata Memorial Centre, Mumbai
Naveen Mummudi Tata Memorial Centre, Mumbai
Neha Sharma Tata Memorial Centre, Mumbai
Niharendu Ghara Tata Medical Center, Kolkata
Nikesh Hanumanthappa Guys and St Thomas's NHS Hospital, London
Nithyanand C Tata Memorial Centre, Mumbai
Nivedhyaa Srinivasaraghavan Cancer Institute, Adayar, Chennai
Nuthan Kumar Mk Kidwai Memorial Institute Of Oncology, Bangalore
Nuworza Kugbey University of Health and Allied Sciences, Ghana
Pooja Ramakant King Georges' Medical University, Lucknow
Preethi S Shetty Tata Memorial Centre, Mumbai
Priyanka Augustine Kasturba Medical College, Manipal
Prriya Eshpuniyani Asian Cancer Institute, Mumbai
Punitha Chockalingam Cancer Institute, Adayar, Chennai
Rasmi Palassery M.S. Ramaiah Medical College, Bangalore
Revathi Rajagopal CyteCare Hospitals, Bangalore
Rutula Sonawane Tata Memorial Centre, Mumbai
Sachit Ganapathy JIPMER, Puduchery
Sandip Kumar Barik Acharya Harihar Regional Cancer Centre, Cuttack
Shyam S Tata Memorial Centre, Mumbai
Sravan Kumar Basavatarakam Indo-American Cancer Hospital, Hyderabad
Sreedevi Warrier Manipal Academy of Higher Education, Manipal
Sucharita Tuladhar Tata Medical Center, Kolkata
Suja Johnson ACTREC, Tata Memorial Centre, Mumbai
Tanma Mahanta Assam Cancer Care Foundation, Guwahati, Assam
Tejshri Telkhade Tata Memorial Centre, Mumbai
Umesh Velu Kasturba Medical College, Manipal
Vadaparty Annapurna Sri Shankara Cancer Hospital & Research Centre, Bangalore
Vandhana Rajgopal All India Institute of Medical Sciences, New Delhi
Vasu Babu Goli Tata Memorial Centre, Mumbai
Venkata Rama Mohan Gollamudi Tata Memorial Centre, Mumbai
Vijay G Cancer Institute, Adayar, Chennai
Vijay Kumar Srinivasalu Narayana Hrudayalaya, Mazumdar Shaw Medical Center, Bangalore
Akshay Patil Tata Memorial Centre, Mumbai
Ajit Venniyoor Ministry of Oman
Binu V S NIMHANS, Bangalore
Maya Padmanabhan Malabar Cancer Centre, Thalassery
Shivam Pandey All India Institute of Medical Sciences, New Delhi
Vineeta Deshmukh Integrated Cancer Treatment and Research Center, Wagholi, Pune
“I have thoroughly enjoyed myself over the past 1 week. My sincere thanks to my entire team of mentors of the PDG and the entire faculty. The
hard work put in by the mentors and the faculty is really commendable. I hope all of us do justice to this hard work” – Prriya Eshpuniyani, Asian
Cancer Institute, Mumbai
“It was a great learning experience for me. All the mentors were very approachable and helpful. The knowledge acquired in these days will be
useful for me not only for this protocol but all my future research projects” – Mayur Mantri, Tata Memorial Centre, Mumbai
“Thank you very much for such a lovely and enriching experience” Dorothy Lombe, Zambia
“Thanks to the organizers of CReDO for such a wonderful 7 days. It changed my perspective of conducting a clinical trial. So much gained and
these 7 days will help me gain even more” – Sandip Barik, Cuttack
“Thank you so much for mentoring us with so much of patience and passion. It was a wonderful opportunity to be mentored by you all” - Arpitha
“It was a memorable experience at CReDO for me- learnt a lot. A big shout out to the whole CReDO team and the faculty!!! – Annapurna
“Thank you very much for a week full of learning and fun. I hope to make you all proud by getting my study done and publishing it! – Rasmi
“Thanks again for organizing such a wonderfully productive, fulfilling, and uplifting week”! – Martin Stockler, Australia
“It was a fascinating, albeit intense, experience! I certainly learned a lot from it, and seeing how the attendees developed from last Sunday
through to their presentations on Friday was remarkable and gratifying in equal measure. You have really created something incredibly
important and transformative.” - David Collingridge, UK
- Research ideas developed at the workshop
1. A Prospective Comparative Analysis Financial Toxicity Within the Public and Private healthcare Systems of India compared with Canada.
2. Development Of A Novel Voice Prosthesis Using Indigenous Design For Post Laryngectomy Voice Rehabilitation
3. A phase II study to evaluate the feasibility of a switch TKI strategy in adolescents and adults with De-Novo Philadelphia positive Acute
Lymphoblastic Leukemia (Ph+ ALL).
4. Comparison of MRI based versus CT based brachytherapy for gynaecological cancers
5. Prospective assessment of Bone Mineral Density Changes after Pelvic Radiotherapy in women with Cervical or endometrial Cancer.
6. ERAS in head and neck commando surgery (with a microvascular free flap) : will an evidence based perioperative protocol impact
7. Self-esteem and quality of life of breast cancer patients following mastectomy and the impact of external breast prosthesis.
8. Radionuclide therapy with 177Lu-PSMA as second line treatment in hormone sensitive prostate cancer versus docetaxel chemotherapy -
A prospective, phase 2, randomized controlled trial.
9. Role of Extensive education about the disease, chemotherapy, benefits of completion of therapy and effective management of side
effects to avoid abandonment of treatment.
10. Postoperative intra-peritoneal chemotherapy after primary cytoreduction- a randomised phase three trial
11. Assessment of High-Risk HPV and p16 expression in Oropharyngeal Cancer for prognostication in North-East India
12. Development and validation of an automated tool to evaluate radiological response to treatment for lung carcinoma
13. A prospective study to evaluate the role of imaging to predict shrinkage patterns post neoadjuvant chemotherapy and its correlation
with histopathological factors.
14. A mixed-methods study of well-being of cancer caregivers in Nepal
15. Pre-exposure prophylaxis (PrEP) in a pediatric oncology unit with year-round exposure to varicella. Aim: To study the efficacy of pre-
exposure acyclovir-prophylaxis in pediatric oncology patients at risk of varicella.
16. Randomised Trial of Neoadjuvant Chemoradiation followed by Surgery and Chemotherapy vs Perioperative Chemotherapy in Esophageal
17. Designing Community - based Models for Breast Cancer Risk Stratification for the Indian Population - an initiative to address the
extremities of low resource settings
18. Validation of ultrasound-based imaging for 3-D brachytherapy planning in the treatment of locally advanced cervical cancer in Zambia
19. Molecular characterization of human papilloma virus (HPV) associated head and neck squamous cell carcinomas in Rwanda
20. A prospective study to evaluate the impact of Narrow Band Imaging(NBI) versus white light directed marginal assessment in achieving
local control for operable oral cavity cancers.
21. Comparing the effect of hypomethylating agents versus standard 7/3 protocol as initial induction chemotherapy for young acute myeloid
22. A randomised study of methotrexate versus paclitaxel followed by methotrexate and celecoxib with or without cyclophosphamide as
metronomic in recurrent non-nasopharyngeal squamous cell carcinomas.
23. Ultrasound Elastography as a predictor of post-operative complications in patients undergoing total thyroidectomy in tertiary care
cancer hospitals: A multicentric, prospective, observational study.
24. Effect of early integration of specialist palliative care for adult patients with hematolymphoid cancers versus usual care : a randomized
25. Clinical outcomes and cost analysis of ERAS pathway for ovarian cancer surgery: a randomised control trial
26. A phase II study to evaluate the activity of 177-Lu-DOTA rituximab in adult patients with relapsed low-grade b-cell lymphomas.
27. Free Fibula Flap versus PMMC flap for the reconstruction of the lateral mandibular defects: A Prospective two-armed comparative study
to evaluate the Qol outcomes and Cost utility Analysis
28. Intravesical BCG: Is Urinary Bladder Ready To Receive It?
29. To study the relationship between flap ischemia time and flap related complications in free flap reconstruction for Head and Neck
30. Spectrum of molecular biomarkers in intra-ductal proliferative lesions of breast. Role of Immunohistochemistry in risk stratification of
the various precancerous lesions of breast.
31. A prospective Randomized trial of IMRT versus Adaptive Radiotherapy in locally advanced Head and Neck Cancers
32. Oral metronomic therapy in metastatic castrate resistant prostate cancer in second and subsequent lines of therapy
33. Adjuvant Radiation therapy to Tumour bed alone In oral Cavity cancer (ARTIC study)
34. A study in elderly patients with Non Hodgkin lymphoma to evaluate the applicability of clinical trial results to the general population: a
prospective cohort study.
35. The Indian Paediatric Oncology Group collaborative multicentre treatment protocol for children and adolescents with relapsed acute
lymphoblastic leukaemia (InPOG ALL R1)
36. Toxicity and safety of single dose radiotherapy (SDRT) to prostate with 14Gy using stereotactic body radiotherapy (SBRT) technique with
rectal spacers in oligometastatic (1-5 metastases) prostate cancer (Pca) patients
37. A prospective study analysing surgeries for differentiated thyroid cancers- is less really more?
- 38. Intraoperative ventilatory strategies and its association with postoperative pulmonary complications(PPC) in patients undergoing one
lung ventilation (OLV) for thoracic surgeries: A randomized controlled trial.
39. Metronomic therapy in children with recurrent or refractory High Risk Neuroblastoma - A phase 2 study
40. Information needs and preferences among cancer patients in Ghana: implications for patient-centred care in a low resource setting
41. Efficacy and safety of pre-operative concurrent chemoradiation in patients with locally advanced breast cancer.
42. Does addition of proactive intra-peritoneal chemotherapy improve recurrence rates in signet rectal adenocarcinoma ? A RCT.
43. An Open Label, Randomized Controlled Phase II Trial comparing Preoperative Chemotherapy followed by Chemo-irradiation vs Chemo-
irradiation alone in Resectable Oesophageal Cancers
44. Perioperative Serum albumin levels and its effect of postoperative outcomes in operated patients of Carcinoma lung and Carcinoma
45. Prospective randomized control Trial to see the association of anesthetic agents and cancer recurrence in primary cancer surgeries by
measuring the Biomarkers released by Natural killer cells.
46. A prospective observational study of cancer in adolescent and young adult (AYA) patients to understand the disease pattern, treatment
outcomes and the voids in treatment adherence and post-treatment rehabilitation.
47. Efficacy of a Psycho-oncology care model to alleviate psychological distress among patients with head and neck cancer: A non-
randomized clinical trial from a tertiary cancer hospital
48. Is Cognitive Behavioral Therapy along with routine counselling more effective for Body Image Dysfunction in Patients with Advanced
Head and Neck Cancers.
49. Bayesian Network modeling for the prognosis of Head and Neck cancer
50. Observation versus Adjuvant Radiotherapy in Post-operative Early Stage Head and Neck Squamous cell Cancer (HNSCC) of Oral Cavity
51. Granulocyte transfusion for severe sepsis in pediatric oncology
52. Relevance of Post-treatment surveillance in Oral Cancer: A prospective observational study
53. Facilitators and barriers in screening for cancers in HIV patients in a community setting in India- A qualitative study
54. Evaluating the safety and feasibility of outpatient management of children with fever and neutropenia during anti-cancer therapy
55. A phase 1/ 2 open-label, dose-escalation, safety and efficacy study of mTORC1 inhibitor, rapamycin, combined with cisplatin-
pemetrexed in KRAS mutant lung cancer.
56. How cultural & social issues impact patients’ health related behavior in accessing health care services, treatment adherence & symptom
57. Optimizing follow up cystoscopy use after bladder preservation in muscle invasive bladder cancer(MIBC)
58. Phase II trial comparing the reduction of radiation dose to the intermediate and low risk region versus conventional radiotherapy doses
in p16 positive head and neck cancer patients
59. Prevalence of HPV infection in rural India from urine sample in the community
60. A randomized control study evaluating the use of oral metronomic chemotherapy versus conventional systemic chemotherapy in LABC;
to further conduct an RCT trial on patients amenable, to breast conservation surgery versus mastectomy after chemotherapy.
61. A Phase II randomised study to evaluate the role and efficacy of Post remission therapy in Acute Myeloid Leukaemia(AML)
62. Levofloxacin prophylaxis in children with Acute Lymphoblastic Leukemia (ALL) -An open label randomised phase III study.
63. Phase III, randomized controlled trial of intraperitoneal chemotherapy versus intravenous chemotherapy after neoadjuvant
chemotherapy and optimal cytoreduction in stage III epithelial carcinoma of ovary/ fallopian tube/ primary peritoneal cancer
64. Study of immune contexture of gastroesophageal tumours